Relatro 25

Indications:

• Relatro is indicated for controlling clinical spasticity in conditions like spinal cord injury, stroke, cerebral palsy, or multiple sclerosis, aiding functional rehabilitation.
• It’s beneficial for patients with reversible spasticity, showing improvement in clonus and reducing the need for nursing care.

Pharmacology:

• Dantrolene in Relatro affects skeletal muscle contractile response beyond the myoneural junction, disrupting excitation-contraction coupling.
• It targets skeletal muscle, interfering with the release of Ca++ from the sarcoplasmic reticulum, inducing relaxation.

Dosage & Administration:

• Adults: Start with 25 mg twice daily, gradually titrating up to a maximum of 400 mg/day. Pediatric dosing varies.
• For malignant hyperthermia prevention, administer 4 to 8 mg/kg/day preoperatively and post-crisis.

Interaction:

• Relatro may cause drowsiness, exacerbated by CNS depressants. Hepatotoxicity risk increases with concomitant estrogen therapy.

Contraindications:

• Avoid in active hepatic diseases like hepatitis and cirrhosis.

Side Effects:

• Common side effects include drowsiness, dizziness, weakness, and diarrhea, often transient and manageable with dose adjustment.

Pregnancy & Lactation:

• Use during pregnancy (Category C) and lactation only if benefits outweigh risks.

Precautions & Warnings:

• Monitor liver function; discontinue if no improvement within 45 days.
• Caution in driving, hazardous occupations, and exposure to sunlight.
• Consider hepatocellular injury risks, especially in females and patients over 35 years.

Special Populations:

• Long-term safety not established in pediatric patients under 5 years.

Therapeutic Class:

• Centrally acting Skeletal Muscle Relaxants

Storage Conditions:

• Store in a cool, dry place, protected from light.